![]() are increasingly diagnosed in both animals and people. Infections with tick-transmitted Babesia spp. canis transmission under field conditions in an endemic area for 12 weeks. Oral administration of Bravecto chewable tablets at the recommended dosage to dogs completely prevented B. Tick analyses revealed that one sample collected in Hungary was infected with B. However, babesiosis infection was diagnosed in five untreated control dogs (Fisher’s exact test, left-sided, P = 0.0312). canis, resulting in calculated efficacy of 100%. During the study period, no fluralaner-treated dog became positive for B. canis DNA or antibodies within 21 days after enrollment. ResultsĪ total of 152 dogs were enrolled in the study, although nine dogs were excluded because they tested positive for B. In addition, ticks collected at monthly intervals throughout the study were identified to species level and females tested for B. canis-positive tests in fluralaner-treated dogs compared with untreated dogs. canis transmission risk based on the difference in B. Efficacy was determined by the percentage reduction in B. canis exposure: on days 0 and 21 (exposure before day 0), during the study and at the end of the tick season (dogs suspected of having become infected after day 0). Blood samples were collected to evaluate B. In Europe, privately owned, clinically healthy pet dogs were enrolled and randomized either to receive fluralaner at 25–56 mg/kg (Bravecto ® chewable tablets) on days 0 and 84, or to remain untreated during the D. canis infection of dogs in endemic areas under natural conditions. This study was designed to evaluate the effectiveness of fluralaner chewable tablets for sustained prevention of B. The isoxazoline fluralaner is effective for prevention of Babesia canis transmission from infected Dermacentor reticulatus ticks to dogs for 84 days in a controlled environment.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |